NCT00489385View on ClinicalTrials.gov

An Open Label Non-Randomized Dose Escalating Trial to Assess Safety and Tolerability of Alb-Interferon Alfa 2b Every Two Weeks With Ribavirin Among HIV/HCV Coinfected Individuals

PHASE1CompletedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

June 18, 2007

Primary Completion Date

March 15, 2011

Study Completion Date

March 15, 2011

Conditions
HIV InfectionsHCV
Interventions
DRUG

Albinterferon

DRUG

Ribavirin

DRUG

Albuferon

Trial Locations (1)

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT00489385 - An Open Label Non-Randomized Dose Escalating Trial to Assess Safety and Tolerability of Alb-Interferon Alfa 2b Every Two Weeks With Ribavirin Among HIV/HCV Coinfected Individuals | Biotech Hunter | Biotech Hunter